by Chris Kamel | Mar 2, 2011
They’re promising, but not perfect. Induced pluripotent stem cells are perhaps one of the most studied areas of stem cell research today, as researchers work to improve their method of production, but new findings out of Canada and Finland suggests that the...
by Chris Kamel | Feb 28, 2011
We’ve talked often about induced pluripotent stem cells (iPS cells) on this blog — the transformation of adult terminally differentiated cells into stem cells that can differentiate into various lineages — mostly in the context of discoveries in mice...
by Stem Cell Network | Jan 27, 2011
Earlier this week, many of the world’s leading scientists engaged in developing stem cell-based treatments for Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) met for the first time as a group to share their work. Held in New York, the meeting was...
by Stem Cell Network | Dec 29, 2010
Earlier this month, the Honourable Tony Clement, Minister of Industry, announced the establishment of the Centre for the Commercialization of Regenerative Medicine (CCRM) with a $15 million initial investment. The CCRM will be based in Toronto and is one of five new...
by Ubaka Ogbogu | Dec 16, 2010
Chris Kamel’s recent post on chemically derived transcription factors for iPS cell production is very exciting for a variety of non-scientific reasons. Most notably, the innovative procedure and future improvements are likely to ease ethical, safety and legal concerns...
Comments